Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Amgen’s Repatha Cholesterol Drug Cuts Risk of Cardiovascular Events in Clinical Trial

XTALKS VITALS NEWS

Along with reducing the risk of heart attacks, strokes and death in patients, the cholesterol-lowering PCSK9 inhibitor was on-par with the placebo in terms of its effect on cognitive function.

Share this!

February 6, 2017 | by Sarah Hand, M.Sc.

Initial results from Amgen’s FOURIER clinical trial show that Repatha reduces the risk of cardiovascular events in patients with heart disease. According to a press release issued by the drugmaker, more detailed results of the study will be presented at the American College of Cardiology (ACC) 66th Annual Scientific Session.

Along with reducing the risk of heart attacks, strokes and death in patients, the cholesterol-lowering PCSK9 inhibitor was on-par with the placebo in terms of its effect on cognitive function. As rare instances of neurocognitive events have occurred in some late-stage PCSK9 clinical trials, these findings help ease concerns that the drug could impair cognition.



Amgen’s previous study – the GLAGOV trial – demonstrated Repatha’s ability to reduce atherosclerosis by lowering cholesterol. The current trial did not uncover any previously-unknown safety issues associated with Repatha.

“These FOURIER results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy,” said Dr. Sean E. Harper, executive vice president of Research and Development at Amgen. “Cardiovascular disease remains the number one health burden in the world, and we look forward to sharing these outcomes data with the scientific community at the ACC 66th Annual Scientific Session.”

The Phase III FOURIER trial involved approximately 27,500 patients who had previously experienced a heart attack, ischemic stroke or symptomatic peripheral artery disease. These patients were all on optimized statin therapy, and were randomly assigned to receive Repatha or a placebo injection, administered bi-weekly.

Repatha is a monoclonal antibody that inhibits the PCSK9 protein. By binding to PCSK9, Repatha prevents the protein from binding to the low-density lipoprotein (LDL) receptor (LDLR), which is responsible for removing LDL cholesterol. Repatha allows the LDLR to perform this function by removing interference from PCSK9, thereby reducing levels of LDL-C in the blood.

Cardiovascular disease is the number one cause of death globally. Approximately 11 million individuals in the US have atherosclerotic cardiovascular disease (ASCVD) and/or familial hypercholesterolemia (FH) that remains uncontrolled with statins alone.


Keywords: PCSK9, Cardiovascular Disease, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.